logo
Plus   Neg
Share
Email

FDA Allows Marketing Of Rapid Diagnostic Test For Detecting Ebola Virus

ebolavirus-oct11-lt.jpg

The U.S. Food and Drug Administration has allowed marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood.

The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. The test provides a rapid, presumptive diagnosis that must be confirmed.

"Today's marketing authorization provides another important tool in the effort to fight Ebola, which continues to be a priority of the U.S. Government, especially as we work with our partners, including the World Health Organization, to help address the current Ebola outbreak in the Democratic Republic of Congo (DRC)," said Acting FDA Commissioner Ned Sharpless.

The current outbreak in the Congo has already killed thousands and the outbreaks in West Africa that began in 2014 tragically killed more than 11,000. Quickly diagnosing the disease could help stopping these outbreaks.

EVD, which is caused by the Ebola virus, is a severe, often fatal disease in humans that can spread through direct contact with blood or body fluids or objects contaminated with body fluids, as well as from the bodies of those who have died from the virus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020. Swiss banking giant UBS Group AG reported lower profit in its third quarter mainly with weak profit in Investment Bank segment and lower net interest income. Looking ahead, the bank noted that geopolitical tensions and trade disputes continue to impact investor confidence. However, positive momentum toward resolving issues would likely improve confidence and the economic outlook.
Follow RTT
>